News Sanofi draws up $9.1bn plan to buy Blueprint Meds Sanofi has bolstered its rare disease business with an agreement to buy Blueprint Medicines and blockbuster-in-waiting Ayvakit for ASM.
News Axe falls on Stealth Bio staff after FDA rejects lead drug Stealth BioTherapeutics' filing for Barth syndrome therapy elamipretide has been turned down by the FDA, but there may be a way forward for the drug.
News Old COVID tweet lands Pfizer in new trouble with PMCPA COVID-19 vaccine tweets from 2020 land Pfizer in trouble for promoting an unlicensed medicine - and reveal the pitfalls of linking content.
News Eisai says patent win blocks Lenvima generic to 2036 Eisai has won a lawsuit blocking FDA approval of Shilpa's generic of cancer blockbuster Lenvima until 2036, although the verdict could go to appeal.
News Manufacturing issues scupper Savara's lead drug filing Savara shares are pummelled after the FDA says it cannot accept a filing for lead drug Molbreevi, but it is still hopeful of an approval in 2026.
News Sanofi admits giving free Olympics tickets to patients Despite a voluntary admission of a breach of the ABPI code, Sanofi is deemed to have "brought discredit" on the pharma industry.
News Bayer trial combines two top drugs for kidney disease Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics.
